Watch Factbox-US Government to Impose Inflation Penalties on 27 Drugs – US Latest News

(Reuters) – The U.S. government said on Wednesday it will subject 27 drugs to inflation penalties, a move that will require the pharmaceutical companies to pay Medicare rebates if they raise prices at a faster pace than the rise in inflation rate.

    Under the new provisions, the government will start invoicing the companies for the rebates in 2025, but Medicare members will see a reduction in out-of-pocket costs starting April.

Here is a list of the drugs and companies:

DRUG NAME USED FOR MANUFACTURER U.S. NET

Humira Arthritis AbbVie Inc $18.62

Yescarta Blood cancer Gilead Sciences $747

Padcev Urothelial cancer  Seagen Inc   $451

Xiaflex    Peyronie’s disease Endo $438.7

Tecartus   Blood cancer Gilead Sciences $221

Mircera  Anemia  Roche 408 million

Fetroja  Serious bladder or Shionogi & Co 7.3 billion

kidney infections Ltd  yen in

Fragmin  Treat blood clots  Pfizer Inc $4 million

Abelcet Invasive fungal Leadiant Data

infections Biosciences unavailable

Akynzeo Prevention of Helsinn Data

chemotherapy-induce Healthcare S.A unavailable

Atgam Used after kidney Pfizer Inc Data

transplant to keep unavailable

Aveed Treat low Endo Data

testosterone in International unavailable

Bicillin Antibiotic Pfizer Inc Data

Bicillin Antibiotic Pfizer Inc Data

Carnitor Carnitine Leadiant Data

deficiency Biosciences unavailable

Cytogam To prevent a Kamada Ltd Data

cytomegalovirus unavailable

Elzonris Rare form of blood Menarini Group Data

Flebogamma Treatment for Grifols SA Data

Folotyn T-cell lymphoma Acrotech Data

Biopharma LLC unavailable

Leukine Blood cancer Partner Data

Minocin To prevent Bausch Health Data

infections in Companies unavailable

Nipent Blood cancer Pfizer Inc Data

Rybrevant Lung cancer Johnson & Data

Signifor For the rare Recordati Data

LAR diseases Acromegaly unavailable

Sylvant Multicentric EUSA Pharma (US) Data

Castleman’s disease LLC unavailable

Winrho SDF Bleeding disorder Kamada Ltd’s Data

Xipere Eye disease macular Bausch and Data

edema associated Lomb’s unavailable

($1 = 0.9217 Swiss francs)

(Compiled by Aditya Samal and Leroy leo; Editing by Shinjini Ganguli)

Copyright 2023 Thomson Reuters.